List of Bulk Drug Substances for Compounding Office Stock Drugs for Use in Nonfood-Producing Animals or Antidotes for Food-Producing Animals; Request for Nominations

A veterinary professional (implied by the context of treating animals) argues in favor of keeping metronidazole on office stock for compounding. They state that having the drug readily available is critical for treating small, young, or debilitated animals and that the compounded version is more palatable and appropriately concentrated than commercial alternatives.

The commenter, likely a veterinary professional, argues that the proposed action is necessary to provide timely treatment for vulnerable patients. They highlight that waiting for patient-specific prescriptions can lead to severe illness or death and emphasize the importance of immediate treatment for zoonotic infections like Giardia.

A veterinary professional (implied by the mention of "patients," "clients," and "dosing") is requesting the inclusion of more medication strengths on the list. They argue that the current limited availability of strengths makes it difficult to provide cost-effective and accurate dosing for aging animals.

A business owner (likely a veterinary clinic or pharmacy) argues that the current list of commercial products is insufficient for many patients due to issues with dosage forms, concentrations, and palatability. They support the proposed action to allow more bulk drug substances for compounding to ensure animals can receive timely and appropriate treatment.

A veterinary professional (implied by the context of "our feline patients" and "veterinary practices") argues that compounded azithromycin should be included in the list of office stock drugs. They explain that current human-marketed versions are unpalatable for cats, and having a compounded version would improve patient compliance and treatment success.